Table 2.
Summary of secondary efficacy outcome findings.
| Outcome variables | Albiglutide arm | Control arm | Number of RCTs (participants) | Pooled effect size, OR/MD (95% CI) |
I 2 (%) | P | Subgroup difference (albiglutide 30 vs 50 mg), P |
|---|---|---|---|---|---|---|---|
| Participants achieving HbA1c < 6.5% | Albiglutide 30 mg | Placebo | 5 (915) | 6.96 (3.17–15.26) | 44 | <.00001 | .25 |
| Albiglutide 50 mg | Placebo | 4 (1192) | 3.73 (1.81–7.67) | 47 | .0004 | ||
| Albiglutide 50 mg | OADs | 3 (1697) | 1.07 (0.74–1.53) | 41 | .73 | NA | |
| Albiglutide 30 mg | GLP-1 RAs | 2 (325) | 1.43 (0.23–8.67) | 85 | .70 | .57 | |
| Albiglutide 50 mg | GLP-1 RAs | 2 (1053) | 0.82 (0.45–1.50) | 73 | .52 | ||
| Albiglutide 50 mg | Insulins | 3 (2102) | 0.98 (0.74–1.30) | 27 | .88 | NA | |
| Participants achieving HbA1c < 7.0% | Albiglutide 30 mg | Placebo | 5 (915) | 6.26 (2.50–15.70) | 82 | <.0001 | .86 |
| Albiglutide 50 mg | Placebo | 4 (1192) | 5.57 (2.25–13.80) | 84 | .0002 | ||
| Albiglutide 50 mg | OADs | 3 (1697) | 1.17 (0.78–1.75) | 71 | .44 | NA | |
| Albiglutide 30 mg | GLP-1 RAs | 2 (325) | 0.76 (0.47–1.21) | 0 | .25 | .79 | |
| Albiglutide 50 mg | GLP-1 RAs | 2 (1053) | 0.83 (0.51–1.34) | 63 | .44 | ||
| Albiglutide 50 mg | Insulins | 3 (2102) | 1.02 (0.85–1.23) | 0 | .84 | NA | |
| Participants achieving HbA1c < 7.5% | Albiglutide 30 mg | Placebo | 2 (496) | 3.51 (2.23–5.54) | 32 | <.00001 | .75 |
| Albiglutide 50 mg | Placebo | 3 (965) | 3.85 (2.81–5.26) | 0 | <.00001 | ||
| Albiglutide 50 mg | OADs | 2 (1422) | 1.08 (0.48–2.40) | 92 | .85 | NA | |
| CFB in FPG (mmol/L) | Albiglutide 30 mg | Placebo | 5 (918) | −1.82 (−2.10–−1.54) | 0 | <.00001 | .96 |
| Albiglutide 50 mg | Placebo | 4 (1202) | −1.83 (−2.30–−1.37) | 62 | <.00001 | ||
| Albiglutide 50 mg | OADs | 3 (1923) | 0.07 (−0.96–1.11) | 94 | .89 | NA | |
| Albiglutide 30 mg | GLP-1 RAs | 2 (325) | −0.04 (−0.84–0.76) | 53 | .92 | .59 | |
| Albiglutide 50 mg | GLP-1 RAs | 2 (1055) | 0.22 (−0.28–0.72) | 74 | .39 | ||
| Albiglutide 50 mg | Insulins | 3 (1988) | 0.04 (−1.14–1.22) | 95 | .95 | NA | |
| CFB in body weight (kg) | Albiglutide 30 mg | Placebo | 5 (916) | 0.28 (−0.24–0.80) | 49 | .30 | .83 |
| Albiglutide 50 mg | Placebo | 4 (1202) | 0.21 (−0.17–0.58) | 0 | .28 | ||
| Albiglutide 50 mg | OADs | 3 (1924) | −2.44 (−4.84–−0.03) | 98 | .05 | NA | |
| Albiglutide 30 mg | GLP-1 RAs | 2 (325) | 0.70 (0.17–1.24) | 0 | .01 | .72 | |
| Albiglutide 50 mg | GLP-1 RAs | 2 (1055) | 0.95 (−0.31–2.22) | 90 | .14 | ||
| Albiglutide 50 mg | Insulins | 3 (1996) | −2.88 (−4.60–−1.16) | 96 | .001 | NA |
CFB = change from baseline, CI = confidence interval, FPG = fasting plasma glucose, GLP-1 RA = glucagon-like peptide-1 receptor agonists, HbA1c = hemoglobin A1c, MD = mean difference, NA = not applicable, OAD = oral anti-hyperglycemic drug, OR = odds ratio, RCTs = randomized controlled trials.